Nektar Therapeutics
Research Nektar Therapeutics (NKTR) on Bullrun: market cap USD 1.53B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNKTR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.53B
- Financial periodQ1 2026
- RevenueUSD 10.86M
- Net income-USD 44.90M
- Free cash flow-USD 44.32M
Valuation Snapshot
latest market cap is USD 1.53B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 55.23M | -USD 164.00M | -USD 208.68M | 100.0% | -9.73 | USD 15.12M | USD 85.75M | USD 89.83M |
| FY2024 | USD 98.43M | -USD 119.00M | -USD 177.18M | 68.8% | -8.68 | USD 44.25M | USD 102.56M | USD 60.74M |
| FY2023 | USD 90.12M | -USD 276.00M | -USD 193.47M | 62.5% | -1.45 | USD 35.28M | USD 117.78M | USD 130.99M |
| FY2022 | USD 92.06M | -USD 368.00M | -USD 309.68M | 76.5% | -1.97 | USD 88.23M | USD 139.46M | USD 366.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.53B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 731.47M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 172.77M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 106.83M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 424.78M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.51B | n/a | n/a | n/a |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nektar Therapeutics's market cap?
Nektar Therapeutics's market capitalization is USD 1.53B.
What does Nektar Therapeutics do?
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.